These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 26349573

  • 41. Speeding up PET/MR for cancer staging of children and young adults.
    Aghighi M, Pisani LJ, Sun Z, Klenk C, Madnawat H, Fineman SL, Advani R, Von Eyben R, Owen D, Quon A, Moseley M, Daldrup-Link HE.
    Eur Radiol; 2016 Dec; 26(12):4239-4248. PubMed ID: 27048532
    [Abstract] [Full Text] [Related]

  • 42. FDG PET/MR for the assessment of lymph node involvement in lymphoma: initial results and role of diffusion-weighted MR.
    Platzek I, Beuthien-Baumann B, Ordemann R, Maus J, Schramm G, Kitzler HH, Laniado M, Kotzerke J, van den Hoff J.
    Acad Radiol; 2014 Oct; 21(10):1314-9. PubMed ID: 25086953
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E, Marit G.
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study.
    Stecco A, Romano G, Negru M, Volpe D, Saponaro A, Costantino S, Sacchetti G, Inglese E, Alabiso O, Carriero A.
    Radiol Med; 2009 Feb; 114(1):1-17. PubMed ID: 19082787
    [Abstract] [Full Text] [Related]

  • 48. Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis.
    Baratto L, Nyalakonda R, Theruvath AJ, Sarrami AH, Hawk KE, Rashidi A, Shen S, States L, Aboian M, Jeng M, Daldrup-Link HE.
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1689-1698. PubMed ID: 36717409
    [Abstract] [Full Text] [Related]

  • 49. Magnetic resonance imaging of malignant lymphoma.
    Vermoolen MA, Kersten MJ, Fijnheer R, van Leeuwen MS, Kwee TC, Nievelstein RA.
    Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
    [Abstract] [Full Text] [Related]

  • 50. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ.
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. 18F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma: A Prospective Study with 18F-FDG PET/CT as the Reference Standard.
    Verhagen MV, Menezes LJ, Neriman D, Watson TA, Punwani S, Taylor SA, Shankar A, Daw S, Humphries PD.
    J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
    Giraudo C, Karanikas G, Weber M, Raderer M, Jaeger U, Simonitsch-Klupp I, Mayerhoefer ME.
    J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
    [Abstract] [Full Text] [Related]

  • 57. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K, Kishi S, Tsuchida T, Yamauchi T, Ikegaya S, Urasaki Y, Fujiwara Y, Ueda T, Okazawa H, Kimura H.
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [Abstract] [Full Text] [Related]

  • 58. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
    Hagtvedt T, Seierstad T, Lund KV, Løndalen AM, Bogsrud TV, Smith HJ, Geier OM, Holte H, Aaløkken TM.
    Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
    [Abstract] [Full Text] [Related]

  • 59. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [Abstract] [Full Text] [Related]

  • 60. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
    Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, Hagberg H, Ahlström H.
    Acta Radiol; 2011 Mar 01; 52(2):173-80. PubMed ID: 21498346
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.